Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) shares were up 2.4% on Thursday . The company traded as high as C$4.65 and last traded at C$4.65. Approximately 53,407 shares traded hands during mid-day trading, an increase of 239% from the average daily volume of 15,737 shares. The stock had previously closed at C$4.54.

A number of analysts have commented on CPH shares. TD Securities increased their price objective on shares of Cipher Pharmaceuticals from C$5.50 to C$6.50 in a report on Monday, August 14th. Bloom Burton downgraded shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 14th.

In other Cipher Pharmaceuticals news, Director Harold Morton Wolkin acquired 35,000 shares of the business’s stock in a transaction on Friday, November 10th. The stock was bought at an average price of C$4.69 per share, for a total transaction of C$164,150.00.

TRADEMARK VIOLATION WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/11/23/cipher-pharmaceuticals-inc-cph-trading-up-2-4.html.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.

Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.